FDA approves first factor XIa inhibitor for secondary stroke prevention
The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk for stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA).
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.